News 13 Mar 2024 PSI developing new cancer therapy Researchers from the Paul Scherrer Institute (PSI) have developed a radiopharmaceutical to combat metastatic neuroendocrine tumors. After having ...
Aktuell 26 Mar 2024 Zürcher Forschende machen Krebstherapie wieder wirksam Forschende der Universität Zürich und des Universitätsspitals Zürich haben herausgefunden, wie mutierte Blutkrebszellen wieder auf eine Immunther...
News 10 Mayo 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
Aktuell 13 Mar 2024 PSI entwickelt neue Krebstherapie Forschende des Paul Scherrer Instituts (PSI) haben ein Radiopharmakon gegen metastasierende neuroendokrine Tumore entwickelt. Mit der erstmaligen...
News 30 Abr 2024 Johnson & Johnson opens Innovation Hub in Allschwil Johnson & Johnson has opened its first J&J Innovation Hub on the European mainland at the Switzerland Innovation Park Basel Area. This represents...
News 17 Abr 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
News 04 Abr 2024 Galderma completes largest IPO on a global level in Q1 Galderma has banked nearly 2.3 billion Swiss francs following its listing on the SIX Swiss Exchange. The pharma firm was therefore responsible fo...
News 26 Mar 2024 Zurich researchers make cancer therapy effective again Researchers from the University of Zurich and University Hospital Zurich have discovered how mutated blood cancer cells can be made to respond to...